Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ODYSSEY: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy of Tradipitant in Treating Inflammatory Lung Injury and Improving Clinical Outcomes Associated With Severe or Critical COVID-19 Infection

Next Previous
X
Search
Trial Profile

ODYSSEY: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy of Tradipitant in Treating Inflammatory Lung Injury and Improving Clinical Outcomes Associated With Severe or Critical COVID-19 Infection

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 15 Oct 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tradipitant (Primary) ; Tradipitant (Primary)
  • Indications COVID 2019 infections; COVID-19 pneumonia
  • Focus Registrational; Therapeutic Use
  • Acronyms COVIDL1; ODYSSEY
  • Sponsors Vanda Pharmaceuticals

    • Most Recent Events

    • 14 Oct 2024 According to a Vanda Pharmaceuticals media release,Vandas recent failure to receive FDA approval for tradipitant, followed by a failed Phase 3 trial that missed its primary endpoint
    • 01 Sep 2021 Results reporting carriers of stop-gain IFNAR2 (NM_000874:exon9:c.C966A:p.Y322X) in cohort of severe COVID-19 patients published in the Journal of Global Antimicrobial Resistance
    • 03 Aug 2021 Primary endpoint has not been met. (Time to improvement on a 7-point ordinal scale as compared to baseline), according to a Vanda Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top